Cart
sales@molnova.com
Home - Products - Others - Other Targets - Abelacimab

Abelacimab

CAS No. 2098724-83-3

Abelacimab( —— )

Catalog No. M36766 CAS No. 2098724-83-3

Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 593 Get Quote
5MG 945 Get Quote
10MG 1520 Get Quote
25MG 2475 Get Quote
50MG 3662 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Abelacimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain.
  • Description
    Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2098724-83-3
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • JMJD7-IN-1

    JMJD7-IN-1 is a potent?JMJD7?inhibitor, with an?IC50?of 6.62 μM. JMJD7-IN-1 shows good inhibitory activity against cells expressing a high level of JMJD7.

  • Tefludazine

    Tefludazine, a novel neuroleptic with a benzindone structure, is a compound with good oral activity and antagonistic effects on dopamine and 5-hydroxytryptamine receptors.

  • Coelenterazine h

    Coelenterazine H is a synthetic derivative of coelenterazine (a light-emitting biomolecule).

Sign In Join Free